Chen Bai Email & Phone Number

• Worked closely with the Senior Director of Chemistry to determine strategy, guide research associates, and oversee the day-to-day operations of the Chemistry group
• Managed one direct report and mentored other junior staff
• Represented the Chemistry team in cross-functional collaborations with Discovery, Analytical Development, and Process Development teams
• Developed, optimized, and troubleshot methods for synthesis, purification, and conjugation of long 140mer guide RNAs and other modified oligonucleotides
• Supervised and executed production of guide RNAs with equal or superior quality attributes, on shorter lead times, and at lower cost compared to externally sourced material
• Evaluated enzymatic and click chemistry ligation methods for convergent synthesis of long RNAs

• Led the bioconjugation function, training other scientists, coordinating in-house efforts, and managing 2-4 CRO FTEs
• Developed and optimized methods for synthesis, purification, and analytical characterization of antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates
• Played a major role in developing the degrader-antibody conjugate platform and its translation into two ADCs now in clinical evaluation by designing payloads, collaborating with Biology teams on lead selection, and.
• Co-led a platform chemistry project team that developed proprietary linker chemistry, evaluated targeted protein degraders as ADC payloads, and explored new bioconjugation methodologies
• Served as the bioconjugation subject matter expert on CMC teams, vetting CDMOs, directing external conjugation process and analytical development, and acting as person-in-plant for engineering runs, leading to the.
• Worked with external vendors and facilities consultants to set up laboratories with full conjugation, purification, and analytical capabilities, first in a startup incubator and then in a dedicated facility

Waltham, MA

• Filled a gap in the company’s technical capabilities by establishing methods for synthesizing and characterizing site-specific antibody-drug conjugates (ADCs).
• Developed and optimized processes for preparing ADCs of indolino-benzodiazepine DNA alkylating agents that were inaccessible by well-established methods, enabling their rapid evaluation and integration into the.
• Played a crucial role in advancing IMGN632, an ADC incorporating multiple unfamiliar technologies, into development on a highly aggressive timeline.
• Proposed, won endorsement from upper management for, and led, as the most junior project leader in the organization, an exploratory project on alternative tumor-targeting scaffolds.
• Quickly established the technical foundation and generated proof of concept data for an exploratory project on modulating antibody-antigen affinity via chemical modifications.
• Contributed to the development of high throughput methods for preparing and analyzing ADCs.

Urbana, IL

• Advisor: Professor John F. Hartwig.
• Developed and expanded the scope of regio- and enantioselective iridium-catalyzed allylic substitution reactions.
• Taught organic chemistry to undergraduate students through online problem-solving sessions, one-on-one discussions, and hands-on instruction in the laboratory.